首页|皮肤黑色素瘤患者的预后及影响因素分析

皮肤黑色素瘤患者的预后及影响因素分析

扫码查看
目的 探讨皮肤黑色素瘤(CM)患者的预后及其影响因素.方法 采用免疫组化法检测481例CM患者的波形蛋白(vimentin)、S100、HMB45、Ki-67、Melan-A表达情况.对CM患者进行随访,根据预后情况将患者分为生存组和死亡组,采用Cox比例风险模型分析CM患者预后的影响因素.结果 481例CM患者随访时间为1~132个月,死亡265例,生存216例,总生存率为44.91%.单因素分析结果显示,两组患者的溃疡情况、Clark分级、淋巴结转移情况及S100、Ki-67表达情况比较,差异均有统计学意义(P<0.01).多因素分析结果显示,Clark分级不是影响CM患者预后的因素(P>0.05);溃疡、淋巴结转移、S100(+++)、Ki-67≥30%均是影响CM患者预后的危险因素(P<0.05).结论 CM患者的预后较差;溃疡、淋巴结转移、S 100(+++)、Ki-67≥30%均是影响CM患者预后的危险因素,可用于评估CM患者的预后情况,有助于临床治疗方案的选择及生存率的提高.
Analysis of the prognosis of cutaneous melanoma and its influencing factors
Objective To investigate the prognosis and its influencing factors of cutaneous melanoma(CM).Method The expression of vimentin,S100,HMB45,Ki-67 and Melan-A in 481 CM patients were detected by immunohistochemi-cal method.All CM patients were followed up and divided into the survival group and the death group according to the prognosis.The influencing factors of prognosis in CM patients were analyzed by Cox proportional hazards model.Result The 481 patients with CM were followed up for 1-132 months,265 patients died and 216 patients survived,and the over-all survival rate was 44.91%.Univariate analysis showed that there were statistically significant differences in ulcer sta-tus,Clark grade,lymph node metastasis,S100 expression,Ki-67 expression between the two groups(P<0.01).Multi-variate analysis showed that Clark grade was not an influencing factor of prognosis in CM patients(P>0.05),and ul-cer,lymph node metastasis,S100(+++)and Ki-67≥30%were risk factors for the prognosis of CM patients(P<0.05).Conclusion The prognosis of CM patients is poor.Ulceration,lymph node metastasis,S100(+++)and Ki-67≥30%are risk factors for the prognosis of CM patients,which can be used to evaluate the prognosis of CM patients and help to se-lect clinical treatment plans to improve the survival rate of patients.

cutaneous melanomaprognosisinfluencing factor

郭婷婷、图荪阿依·吾麦尔、胡佳捷、杨丽丽

展开 >

新疆医科大学第五附属医院病理科,乌鲁木齐 830011

新疆医科大学附属肿瘤医院病理科,乌鲁木齐 830011

皮肤黑色素瘤 预后 影响因素

新疆维吾尔自治区自然科学基金

2022D01C302

2024

癌症进展
中国医学科学院,北京协和医学院

癌症进展

影响因子:1.004
ISSN:1672-1535
年,卷(期):2024.22(2)